We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Karim Dabbagh was appointed President and CEO of Second Genome in 2018, where he joined as the Chief Scientific Officer in 2014. Prior to that, he served as Vice President of R&D at Pfizer where he led the Immunoregulation department, an R&D group focused on innovative approaches to elicit homeostatic immune responses for the treatment of immune related disorders. At Pfizer, he also led External R&D Innovation for Immunology, Neurosciences and Cardiovascular/Metabolic Therapy Areas. Before joining Pfizer, Karim was the founder of Modus BioMedicine, a biotechnology company focused on treatments for transplantation and autoimmune disease. Karim also spent nine years at Roche in Inflammation Discovery Research. Karim obtained his PhD in Biochemistry from University College, London and his BSc (Hons) in Biotechnology from Imperial College of Science, Technology, and Medicine in London. He completed postdoctoral fellowships at the University of California, San Francisco and Stanford.
This speaker's sessions: